- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT NG-350A GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA | - | HKEx | ||
| 22.10. | XUANZHUBIO-B (02575): VOLUNTARY ANNOUNCEMENT ANNOUNCEMENT OF PHASE III CLINICAL STUDY DATA OF BIREOCICLIB FOR FIRST-LINE TREATMENT OF HR+/HER2 - ADVANCED ... | 2 | HKEx | ||
| 15.10. | XUANZHUBIO-B Closes Up 126.7% to $26.3 | 1 | AASTOCKS | ||
| 15.10. | XUANZHUBIO-B Closes Up 128.4% to $26.5 at Midday | 1 | AASTOCKS | ||
| 15.10. | SIHUAN PHARM (00460): UPDATE ON THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF XUANZHU BIOPHARM ON THE MAIN BOARD OF THE STOCK EXCHANGE OF HONG KONG LIMITED ... | 1 | HKEx | ||
| 15.10. | XUANZHUBIO-B Opens Up 154% to $29.46 on Debut | 5 | AASTOCKS | ||
| XUANZHU BIOPHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 14.10. | XUANZHUBIO-B (02575): ANNOUNCEMENT OF ALLOTMENT RESULTS | - | HKEx | ||
| 14.10. | XUANZHUBIO-B Closes Up 172.4% to $31.6 on Gray Mkt | 1 | AASTOCKS | ||
| 14.10. | XUANZHUBIO-B (02575): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | 1 | HKEx | ||
| 14.10. | XUANZHUBIO-B (02575): TERMS OF REFERENCE AND RULES OF PROCEDURE OF THE NOMINATION COMMITTEE OF THE BOARD | 2 | HKEx | ||
| 14.10. | XUANZHUBIO-B (02575): TERMS OF REFERENCE AND RULES OF PROCEDURE OF THE REMUNERATION AND APPRAISAL COMMITTEE OF THE BOARD | 1 | HKEx | ||
| 14.10. | XUANZHUBIO-B (02575): TERMS OF REFERENCE AND RULES OF PROCEDURE OF THE AUDIT COMMITTEE OF THE BOARD | 1 | HKEx | ||
| 14.10. | XUANZHUBIO-B (02575): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 06.10. | SIHUAN PHARM (00460): UPDATE ON THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF XUANZHU BIOPHARM ON THE MAIN BOARD OF THE STOCK EXCHANGE OF HONG KONG LIMITED ... | - | HKEx | ||
| 06.10. | SIHUAN PHARM Spins Off XUANZHUBIO-B for IPO Starting Tdy; Entry Fee $5,858.5 | 2 | AASTOCKS | ||
| 06.10. | XUANZHUBIO-B (02575): GLOBAL OFFERING | 3 | HKEx | ||
| 17.09. | SIHUAN PHARM (00460): UPDATE ON THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF XUANZHU BIOPHARM ON THE MAIN BOARD OF THE STOCK EXCHANGE OF HONG KONG LIMITED ... | 3 | HKEx | ||
| 04.09. | SIHUAN PHARM (00460): UPDATE ON THE PROPOSED SPIN-OFF AND SEPARATE LISTING OF XUANZHU BIOPHARM ON THE MAIN BOARD OF THE STOCK EXCHANGE OF HONG KONG LIMITED ... | - | HKEx | ||
| 22.08. | SIHUAN PHARM (00460): VOLUNTARY ANNOUNCEMENT-THE INNOVATIVE DRUG DIROZALKIB TABLETS INDEPENDENTLY DEVELOPED BY XUANZHU BIOPHARM OBTAINED DRUG REGISTRATION ... | 2 | HKEx | ||
| 15.05. | SIHUAN PHARM (00460): VOLUNTARY ANNOUNCEMENT THE CLASS 1 INNOVATIVE DRUG BIREOCICLIB TABLETS INDEPENDENTLY DEVELOPED BY XUANZHU BIOPHARMACEUTICAL, AS ... | 2 | HKEx |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 69,71 | 0,00 % | Novartis kündigt die milliardenschwere Übernahme von Avidity Biosciences an, um damit das eigene Portfolio zu stärken | Bereits im Sommer wurde darüber gemunkelt, nun gibt es auch Gewissheit: Novartis übernimmt das US-Biotechunternehmen Avidity Biosciences und greift dafür tief in die Tasche. Zwölf Milliarden US-Dollar... ► Artikel lesen | |
| 89BIO | 14,855 | +0,13 % | F. Hoffmann-La Roche Ltd: Roche purchases shares in tender offer for 89bio, Inc | Basel, 30 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche's wholly owned subsidiary Bluefin Merger Subsidiary, Inc., has accepted for payment all shares validly tendered... ► Artikel lesen | |
| ERNEXA THERAPEUTICS | 1,790 | 0,00 % | Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer | THE WOODLANDS, Texas, and CAMBRIDGE, Mass., Oct. 29, 2025 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,010 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome | The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,870 | 0,00 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| APOGEE THERAPEUTICS | 55,70 | 0,00 % | Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million | SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
| PURPLE BIOTECH | 1,055 | 0,00 % | Purple Biotech Ltd.: Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform | Achieved commercially viable yield for IM1240, positioning the program competitively for future development Validates scalability of the CAPTN-3 tri-specific antibody platform IM1240, the first CAPTN-3... ► Artikel lesen | |
| QIAGEN | 40,545 | -1,06 % | QIAGEN N.V.: QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing | QIAcube Connect drives lab efficiency by automating critical steps in molecular biology workflows for both research and clinical customers Milestone builds on nearly 13,000 cumulative placements... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,250 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results | Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and... ► Artikel lesen | |
| DYNE THERAPEUTICS | 23,650 | 0,00 % | Why Dyne Therapeutics Stock Crushed the Market on Monday | ||
| PHATHOM PHARMACEUTICALS | 13,530 | 0,00 % | Phathom Pharmaceuticals, Inc. - 10-Q, Quarterly Report | ||
| EVOTEC | 7,088 | -0,87 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,740 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 37,420 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth -- ARCALYST 2025 expected net product revenue raised to $670 - $675 million -- KPL-387... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 11,410 | 0,00 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants | EMERYVILLE, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted... ► Artikel lesen |
XUANZHU BIOPHARMACEUTICAL CO LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XUANZHU BIOPHARMACEUTICAL CO LTD finden Sie auf Wallstreet Online.